Bio-Pharm

DongKook Pharmaceutical strengthens its cosmetics business by acquiring ReBom Cosmetics. On the 16th, DongKook…

STGen Bio announced on the 14th that its Songdo Bio Plant has received current Good Manufacturing Practice (cGMP)…

Hugel has won the final ruling in the botulinum toxin-related lawsuit it faced against Medytox in the United States…

Liga-Chem Biosciences announced on the 10th that it had signed two licensing agreements with Ono Pharmaceutical, a…

Orum Therapeutics, a biotechnology company preparing for its KOSDAQ listing, announced its goal to achieve sales of KRW…

There is an evaluation that Samsung Biologics' stock could rise in the short term if the U.S. Biosecurity Law is passed.…

Celltrion has officially entered the ASEAN market by establishing a local subsidiary in Vietnam. Following the company's…

Celltrion announced on the 27th that it has launched a media campaign in the U.S. for "Zymfentra," the world’s only…

HK inno.N's novel drug for gastroesophageal reflux disease (GERD), K-CAB, has received marketing approval in Malaysia.…

Samsung Biologics announced on the 25th that it has introduced two new Contract Development Organization (CDO) platforms…

The government has selected the ‘Korea Value Up’ Index as part of its efforts to address the Korea Discount, and 12…

Lunit, a leading medical AI company focused on developing solutions that extend beyond diagnosis into treatment, is…

Yuhan Corporation announced on the 11th that it will receive $60 million (approximately 80 billion KRW) in…

The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the…

Park Jaehyun, CEO of Hanmi Pharmaceutical, retained his position following a board decision that rejected the…

SK Biopharmaceuticals has set an ambitious goal to emerge as a global player in the radiopharmaceutical(RPT) sector…

Celltrion has signed a listing agreement for Zymfentra with the major U.S. insurer Cigna, following its successful…

There is a growing consensus that aesthetic-focused companies, which demonstrated strong stock performance in Q2, will…

Voronoi, a drug development specialist that recently licensed out its autoimmune disease treatment pipeline to a…

"When coincidences accumulate, they become inevitable. The fact that LECLAZA, which I once crossed paths with, came back…